Lexicon Pharmaceuticals (LXRX) Enterprise Value (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Enterprise Value of -$170.7 million for Q1 2026, up 12.41% year-over-year from -$151.8 million in Q1 2025, and down 77.34% quarter-over-quarter from -$96.2 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Enterprise Value (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Enterprise Value for 17 consecutive years, with -$170.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 12.41% year-over-year to -$170.7 million; the TTM figure through Mar 2026 stood at -$170.7 million (up 12.41% YoY), while the FY2025 annual figure was -$96.2 million, up 59.56% from the prior year.
- Enterprise Value retreated to -$170.7 million in Q1 2026 per LXRX's latest filing, from -$96.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$62.0 million in Q2 2022 and bottomed at -$355.6 million in Q1 2024.
- Historically, Enterprise Value has averaged -$179.6 million across 5 years, with a median of -$170.0 million in 2023.
- Annual changes were most pronounced in 2023 — Enterprise Value plunged 314.31% — and 2025, when it soared 59.56%.
- Lexicon Pharmaceuticals' Enterprise Value stood at -$138.4 million in 2022, then decreased by 22.89% to -$170.0 million in 2023, then sank by 39.95% to -$238.0 million in 2024, then jumped by 59.56% to -$96.2 million in 2025, then tumbled by 77.34% to -$170.7 million in 2026.
- Business Quant data shows LXRX's Enterprise Value at -$170.7 million in Q1 2026, -$96.2 million in Q4 2025, and -$116.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -190.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -190.61 Mn |
| Mar 31, 2026 | -170.66 Mn |
| Dec 31, 2025 | -96.23 Mn |
| Sep 30, 2025 | -115.95 Mn |
| Jun 30, 2025 | -139.01 Mn |
| Mar 31, 2025 | -194.84 Mn |
| Dec 31, 2024 | -237.96 Mn |
| Sep 30, 2024 | -258.37 Mn |
| Jun 30, 2024 | -309.96 Mn |
| Mar 31, 2024 | -355.60 Mn |
| Dec 31, 2023 | -170.03 Mn |
| Sep 30, 2023 | -218.43 Mn |
| Jun 30, 2023 | -256.74 Mn |
| Mar 31, 2023 | -105.94 Mn |
| Dec 31, 2022 | -138.36 Mn |
| Sep 30, 2022 | -136.20 Mn |
| Jun 30, 2022 | -61.97 Mn |
| Mar 31, 2022 | -86.50 Mn |
| Dec 31, 2021 | -86.74 Mn |
| Sep 30, 2021 | -120.92 Mn |